Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community‐Acquired Pneumonia

This publication has 14 references indexed in Scilit:

• Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study
  Journal of Antimicrobial Chemotherapy, 2007
• Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
  The Journal of Infectious Diseases, 2005
• Daptomycin: Another Novel Agent for Treating Infections Due to Drug‐Resistant Gram‐Positive Pathogens
  Clinical Infectious Diseases, 2004
• Randomized, Multicentre Study of the Efficacy and Tolerance of Azithromycin versus Clarithromycin in the Treatment of Adults with Mild to Moderate Community-Acquired Pneumonia
  European Journal of Clinical Microbiology & Infectious Diseases, 1998
• A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin–clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome
  International Journal of Antimicrobial Agents, 1998
• A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
  New England Journal of Medicine, 1997
• Community-Acquired Pneumonia
  New England Journal of Medicine, 1995
• Comparison of the Invesligalional drug, LV146032, with vancomycin in experimental pneumonia due to methidillln-resistant Staphylococcus aureus
  Journal of Antimicrobial Chemotherapy, 1988
• LY146032 in a Hamster Model of Staphylococcus aureus Pneumonia – Effect on in vivo Clearance and Mortality and in vitro Opsonophagocytic Killing
  Chemotherapy, 1988
• STUDIES ON PNEUMONIA IN CHILDREN
  Journal of Clinical Investigation, 1930